Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of ...

In a first-of-its-kind procedure, Ruben Olivares, MD, urologist at Cleveland Clinic, supported a robotic-assisted focal therapy for prostate cancer happening in Abu Dhabi from the US. The procedure ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer ...

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...